<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030185</url>
  </required_header>
  <id_info>
    <org_study_id>2009-AAR-002</org_study_id>
    <nct_id>NCT01030185</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance</brief_title>
  <acronym>PIONEER</acronym>
  <official_title>A Prospective, Multi-center, Open Label, Non-randomized Study to Investigate the Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaShunt AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaShunt AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and performance of the Automated Fluid Shunt in patients with
      ascites and diuretic resistance.

      Study Size and Duration The primary study population will include 40 patients enrolled and
      implanted with the NovaShunt Automated Fluid Shunt (AFS) in up to 15 centers in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of the NovaShunt AFS will be evaluated by the incidence and severity of device- and procedure-related serious adverse events</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Paracentesis requirements</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemodynamic instability</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of peripheral edema</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>NovaShunt's Automated Fluid Shunt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Automated Fluid Shunt (AFS) Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovaShunt's Automated Fluid Shunt implantation</intervention_name>
    <description>The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.</description>
    <arm_group_label>NovaShunt's Automated Fluid Shunt</arm_group_label>
    <other_name>NovaShunt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age

          -  Recurrence of ascites defined as clinical reappearance of ascites within 4 weeks of
             initial paracentesis.

          -  Cirrhosis of any etiology

          -  Failure to respond to a maximum of 160 mg/d of furosemide and 400 mg/d of
             spironolactone (or equivalent doses of loop-acting and distal-acting diuretics), or
             intolerance to high dose diuretics because of hyponatremia, hyperkalemia, or other
             side-effects

          -  Dietary sodium restriction &lt;88mEq/d.

          -  Serum creatinine levels of ≤ 2.0 mg/dL for at least 7 days before study entry.

          -  Total bilirubin levels of less than 3 mg/dL.

          -  Expected survival of greater than 6 months

          -  Written informed consent

          -  Ability to comply with study procedures and ability to operate the device.

          -  Women of childbearing age should use adequate contraceptives

        Exclusion Criteria:

          -  Presence of recurring systemic or local infection, such as peritonitis, urinary tract
             infection, or abdominal skin infection.

          -  Presence of peritoneal carcinomatosis

          -  Advanced hepatocellular carcinoma, demonstrated by:

               1. One tumor that is &gt;5 cm diameter

               2. 3 or more nodules of &gt;3 cm diameter

               3. Portal thrombosis

          -  Other evidence of a malignant Etiology for Ascites

          -  Evidence of extensive ascites loculation

          -  Gastrointestinal hemorrhage due to portal hypertension in the 2 weeks prior to the
             inclusion in the study.

          -  Hepatic encephalopathy in the two weeks prior to implant

          -  Presence of a TIPS or surgical portosystemic shunt

          -  Presence of Budd-Chiari syndrome

          -  Previous liver transplant

          -  Obstructive uropathy

          -  Coagulopathy that could not be corrected to a prothrombin time INR &lt;1.8,

          -  Thrombocytopenia that could not be corrected to a platelet count greater than
             60,000/mm3

          -  Any other clinically significant disease that could be adversely affected by study
             participation judged by the Investigator

          -  Any condition requiring emergency treatment

          -  Pregnancy

          -  Patients being in another clinical study that did not reach primary endpoint yet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Such, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Uneversitario de Alicante C/ Maestro Alonso 109 - 03010 Alicante /Alacant, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of hepatology, UZ Leuven, campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Internal Diseases, MHAT &quot;Tokuda Hospital Sofia&quot; JSC</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Clinica of Gastroenterology and Hepatology</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie Charité, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Uneversitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Pau I Sant Creu</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ascites</keyword>
  <keyword>liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

